IL273196B2 - Claudin6 antibodies and methods of treating cancer - Google Patents

Claudin6 antibodies and methods of treating cancer

Info

Publication number
IL273196B2
IL273196B2 IL273196A IL27319620A IL273196B2 IL 273196 B2 IL273196 B2 IL 273196B2 IL 273196 A IL273196 A IL 273196A IL 27319620 A IL27319620 A IL 27319620A IL 273196 B2 IL273196 B2 IL 273196B2
Authority
IL
Israel
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Application number
IL273196A
Other languages
English (en)
Hebrew (he)
Other versions
IL273196B1 (en
IL273196A (en
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL273196A publication Critical patent/IL273196A/en
Publication of IL273196B1 publication Critical patent/IL273196B1/en
Publication of IL273196B2 publication Critical patent/IL273196B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
IL273196A 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer IL273196B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Publications (3)

Publication Number Publication Date
IL273196A IL273196A (en) 2020-04-30
IL273196B1 IL273196B1 (en) 2024-07-01
IL273196B2 true IL273196B2 (en) 2024-11-01

Family

ID=65723110

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273196A IL273196B2 (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer
IL313238A IL313238A (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL313238A IL313238A (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer

Country Status (22)

Country Link
US (4) US20200291111A1 (enExample)
EP (2) EP3826667B1 (enExample)
JP (2) JP7599332B2 (enExample)
KR (2) KR102793719B1 (enExample)
CN (2) CN111565744B (enExample)
AU (2) AU2018334434B2 (enExample)
BR (1) BR112020005196A2 (enExample)
CA (1) CA3076207A1 (enExample)
CZ (1) CZ2021138A3 (enExample)
DK (1) DK3826667T3 (enExample)
ES (1) ES2986343T3 (enExample)
FI (1) FI3826667T3 (enExample)
GB (1) GB202103867D0 (enExample)
HU (1) HUE067603T2 (enExample)
IL (2) IL273196B2 (enExample)
MX (2) MX2020002921A (enExample)
NO (1) NO20210351A1 (enExample)
PL (1) PL3826667T3 (enExample)
PT (1) PT3826667T (enExample)
SG (1) SG11202002114RA (enExample)
SI (1) SI3826667T1 (enExample)
WO (1) WO2019056023A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20210351A1 (en) * 2017-09-18 2021-03-18 Univ California Claudin6 antibodies and methods of treating cancer
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
AU2020223293A1 (en) 2019-02-15 2021-08-19 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
SI3941946T1 (sl) * 2019-03-20 2025-09-30 The Regents Of The University Of California Protitelesa proti klavdinu-6 in konjugati zdravil
CA3134056A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
JP2023529557A (ja) * 2020-05-04 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ｅｎｐｐ１抗体の阻害
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
KR20240153421A (ko) * 2022-02-09 2024-10-22 세라 프로그노스틱스 인코포레이티드 Shbg 및 ibp4 항체 및 이를 사용하는 방법
KR20250114330A (ko) 2022-11-30 2025-07-29 인테그럴 몰큘러 인코포레이티드 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
WO2025146161A1 (en) * 2024-01-04 2025-07-10 Hansoh Bio Llc Antibody, antigen-binding fragment and medical use thereof
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156018A1 (en) * 2011-05-13 2012-11-22 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
CA1264738A (en) 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
KR20010040819A (ko) 1998-02-10 2001-05-15 가마꾸라 아끼오 제어방출형 제제
US6630124B1 (en) 1998-10-16 2003-10-07 Ramot-University Authority For Applied Research And Industrial Development Ltd. Combination therapy with VIP antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
EP2103628A4 (en) * 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
RU2422134C1 (ru) 2007-04-19 2011-06-27 Донг-А Фармасьютикал. Ко., Лтд Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав
SG187457A1 (en) * 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10053511B2 (en) * 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
DK3126381T4 (da) * 2014-04-01 2022-04-04 Biontech Cell&Gene Therapies Gmbh Claudin-6-specifikke immunoreceptorer og t-celleepitoper
NO20210351A1 (en) * 2017-09-18 2021-03-18 Univ California Claudin6 antibodies and methods of treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156018A1 (en) * 2011-05-13 2012-11-22 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6

Also Published As

Publication number Publication date
EP3826667A2 (en) 2021-06-02
US20240400674A1 (en) 2024-12-05
MX2020002921A (es) 2020-09-28
US20220372134A1 (en) 2022-11-24
HUE067603T2 (hu) 2024-10-28
JP2020536507A (ja) 2020-12-17
CZ2021138A3 (cs) 2021-09-15
AU2018334434A1 (en) 2020-04-02
CN111565744A (zh) 2020-08-21
PT3826667T (pt) 2024-08-02
BR112020005196A2 (pt) 2020-09-15
KR20200070238A (ko) 2020-06-17
KR102793719B1 (ko) 2025-04-08
AU2025200467A1 (en) 2025-04-10
CN111565744B (zh) 2024-12-31
EP4435009A2 (en) 2024-09-25
JP2024150445A (ja) 2024-10-23
EP3826667A4 (en) 2022-07-27
JP7599332B2 (ja) 2024-12-13
IL313238A (en) 2024-07-01
FI3826667T3 (fi) 2024-07-22
KR20250050137A (ko) 2025-04-14
WO2019056023A3 (en) 2019-05-16
NO20210351A1 (en) 2021-03-18
EP3826667B1 (en) 2024-04-17
WO2019056023A2 (en) 2019-03-21
US20200291111A1 (en) 2020-09-17
SI3826667T1 (sl) 2024-09-30
PL3826667T3 (pl) 2024-09-30
CA3076207A1 (en) 2019-03-21
GB202103867D0 (en) 2021-05-05
ES2986343T3 (es) 2024-11-11
SG11202002114RA (en) 2020-04-29
US20250333501A1 (en) 2025-10-30
CN118667021A (zh) 2024-09-20
IL273196B1 (en) 2024-07-01
MX2025012685A (es) 2025-11-03
AU2018334434B2 (en) 2025-01-23
IL273196A (en) 2020-04-30
EP4435009A3 (en) 2025-02-26
DK3826667T3 (da) 2024-07-22

Similar Documents

Publication Publication Date Title
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
CN113015749B (zh) 靶向cd3的抗体、双特异性抗体及其用途
JP6709215B2 (ja) 抗ｔｉｍ−３抗体
JP6719477B2 (ja) 抗ｔｉｍ−３抗体
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
JP7649744B2 (ja) Ｂｔｎ３ａ結合タンパク質及びその使用
JP2020522261A5 (enExample)
JP2021500916A5 (enExample)
JP2018532383A5 (enExample)
JP2020536488A5 (enExample)
FI3515487T3 (fi) Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja
JP2020534830A5 (enExample)
HRP20250850T1 (hr) Antitijela protiv claudina 18.2 korisna u dijagnozi raka
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2013506428A5 (enExample)
IL261666B1 (en) Binding proteins and methods of use thereof
JP2016516400A5 (enExample)
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
RU2016100892A (ru) Антитела против tweakr и их применение
JP2013535191A5 (enExample)
JP2019534892A5 (enExample)
JP2017521054A5 (enExample)
JP2015508056A5 (enExample)
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
JP2016529213A5 (enExample)